SK Bioscience announced that Nuvaxovid, Korea's first synthetic antigen coronavirus vaccine, was first shipped from L House in Andong, North Gyeongsang Province this morning. The amount of vaccine shipped by the end of this month is about 2 million doses.
Nuvaxovid is a synthetic antigen-based COVID-19 vaccine developed by US bio company Novavax and manufactured by SK Bioscience from stock solution to finished product.
On January 12, SK Bioscience received an item approval from the Ministry of Food and Drug Safety for New Bag Sod in the form of a pre-filled syringe.
Nuvaxovid is the first synthetic antigen-based COVID-19 vaccine and is expected to create a market differentiated from existing vaccines.
The synthetic antigen-based vaccine platform is used for a long time in existing vaccines such as influenza (flu), hepatitis B, and cervical cancer, and its safety and efficacy have been proven.
In addition, it can be stored under refrigeration conditions of 2 to 8 degrees, so it can be distributed using the existing vaccine distribution network, and thawing is unnecessary during the inoculation stage.
Nuvaxovid has been confirmed to have a preventive effect and safety of up to 90% through large-scale global clinical trials of Novavax.
In particular, it is expected that the immune response to variants including Omicron, which is currently the dominant species, will be confirmed through Novavax's own research and will be used importantly in the prevention of COVID-19.
SK Bioscience has proven its unrivaled technological prowess by exclusively producing and supplying two of the five vaccines that have been approved for inoculation in advanced countries such as the US and EU.
